SEC Filings
|
|
|
|
Filing Date |
Form |
Description |
|
March 22, 2021 |
6-K |
Biophytis gives update on its Phase 2-3 COVA study on COVID-19 |
 |
March 19, 2021 |
6-K |
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd |
 |
March 12, 2021 |
6-K |
Annual General Meeting will take place on April 26, 2021 |
 |
March 11, 2021 |
20-F |
Annual Report for the Fiscal Year Ended Dec 31, 2020 |
 |
Feb 26, 2021 |
6-K |
Biophytis Reports 2020 Full Year Results |
 |
Feb 17, 2021 |
6-K |
Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial |
 |
Feb 16, 2021 |
6-K |
Report of Foreign Private Issuer |
 |
Feb 9, 2021 |
|
Final Prospectus |
 |
Feb 9, 2021 |
F-1 |
Amendment No 3 |
 |
Feb 8, 2021 |
FWP |
Free Writing Prospectus |
 |
Feb 4, 2021 |
F-8A |
For Registration of Certain Classes of Securities Pursuant to Section 12(b) or (g) |
 |
Feb 4, 2021 |
F-1 |
Amendment No 2 |
 |
Feb 2, 2021 |
FWP |
Free Writing Prospectus |
 |
Feb 2, 2021 |
F-1 |
Amendment No 1 |
 |
Jan 19, 2021 |
F-1 |
Form F-1 |
 |
Dec 23, 2020 |
F-1 |
Draft Registration Statement |
 |
Nov 20, 2020 |
F-1 |
Draft Registration Statement |
 |